Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH Trial)

Plain-language summary

This phase 2 randomized controlled trial (SYNERGY-NASH) evaluated tirzepatide over 52 weeks in participants with metabolic dysfunction-associated steatohepatitis (MASH) and moderate or severe liver fibrosis. Treatment with tirzepatide was significantly more effective than placebo at achieving resolution of MASH without worsening of fibrosis, opening a potential new therapeutic application for this dual incretin receptor agonist peptide. The authors noted that larger and longer trials are needed to further confirm efficacy and safety in this population.